The Rivelin Plain Patch is developed as a CE marked product to be used as mechanical barrier occluding mucosal ulcers and inflammation.
The Rivelin Clobetasol Patch is developed for Oral Lichen Planus (OLP). A randomized, double-blind, placebo-controlled, parallel group, multiple centre study in EU and US will be launched in Q4 2017. The aim is to assess the safety and efficacy of three doses of clobetasol and placebo when administered intra-orally twice daily in patients with painful OLP using the Rivelin clobetasol patch in a concentration of: 1 µg, 5 µg, and 20 µg per patch, dosed twice daily for two weeks with the option to dose for an additional two weeks. The dosing period will be followed by a two weeks follow up.